In addition, DMEA also identified that EGFR inhibitor-resistant cells may be sensitive to MDM inhibitors (Fig. 6A,B; Additional file 1: Fig. S5), a finding that is supported by published work showing that MDM2 mediates resistance to EGFR inhibitors in mouse models of NSCLC [56]. This evidence concerns the gene MDM2 and non-small cell lung carcinoma.